Skip to main content

New French Proteomics Firm Launches

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Promise Advanced Proteomics, a French fee-for-service proteomics firm providing mass spectrometry-based absolute quantification services, has launched.

Based in Grenoble, France, Promise is a spinout of the Exploring the Dynamics of Proteomes laboratory at the National Institute of Health and Medical Research, the French Atomic Energy and Alternative Energies Commission, and Université Joseph Fourier. The company officially launched late last month, said Virginie Brun, the company's co-founder and chief scientific officer who was part of a team that developed the company's technology.

Promise provides services for the development of therapeutic proteins and biomarkers. Specifically, it employs a technology called Protein Standard Absolute Quantification for developing full-length isotopically-labeled proteins. The proteins can be used for quantitative proteomics and analytical research.

The technology was developed by researchers at the Exploring the Dynamics of Proteomes laboratory and was described in a 2007 interview with Brun by GenomeWeb Daily News' sister publication ProteoMonitor.

Promise holds an exclusive license to use the PSAQ technology, Brun said.

Nicolas Mouz is Promise's president and CEO.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.